TrialActa oncologica (Stockholm, Sweden)2025

TCHL - a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysis.

John Crown et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.